Previous Article | Next Article ![]()
Journal of Virology, November 2000, p. 10581-10588, Vol. 74, No. 22
AIDS Molecular Biology Unit, National Centre
in HIV Virology Research, Macfarlane Burnet Centre for Medical
Research, Fairfield, Victoria 3078,1 and
National Centre in HIV Epidemiology and Clinical Research,
University of New South Wales,2 and HIV
Medicine Unit and Centre for Immunology, St. Vincent's
Hospital,3 Sydney, New South Wales 2010, Australia
Received 23 December 1999/Accepted 23 August 2000
Long-term survivors (LTS) of human immunodeficiency virus type 1 (HIV-1) infection provide an opportunity to investigate both viral and
host factors that influence the rate of disease progression. We have
identified three HIV-1-infected individuals in Australia who have been
infected for over 11 years with viruses that contain deletions
in the nef and nef-long terminal repeat
(nef/LTR) overlap regions. These viruses differ from each
other and from other nef-defective strains of HIV-1
previously identified in Australia. One individual, LTS 3, is
infected with a virus containing a nef gene with a
deletion of 29 bp from the nef/LTR overlap region,
resulting in a truncated Nef open reading frame. In addition to the Nef
defect, only viruses containing truncated Vif open reading frames of 37 or 69 amino acids could be detected in peripheral blood mononuclear
cells isolated from this patient. LTS 3 had a viral load of less than 20 copies of RNA/ml of plasma. The other two long-term survivors, LTS 9 and LTS 11, had loads of less than 200 copies of RNA/ml of plasma and
are infected with viruses with larger deletions in both the
nef alone and nef/LTR overlap regions. These
viruses contain wild-type vif, vpu, and
vpr accessory genes. All three strains of virus had
envelope sequences characteristic of macrophagetropic viruses. These
findings further indicate the reduced pathogenic potential of
nef-defective viruses.
A small percentage (<5%) of
human immunodeficiency virus type 1 (HIV-1)-infected individuals remain
free from AIDS-defining illnesses for longer than 10 years in the
absence of therapy (4). Individuals in this group
maintaining CD4-positive lymphocyte counts greater than 500 cells/µl without receiving therapy are known as long-term
nonprogressors (LTNP). The factors involved in the long-term survival
of these patients have been the subject of intense investigations as
they may provide information important to the development of HIV-1
vaccines and treatments.
Several factors associated with delayed or slow progression have
been identified and include coreceptor (CCR5 and CCR2b) genotype (6, 30), HLA alleles (25), and, in a few
individuals, virus genotype. Several defects in the viral genome of
HIV-1 strains infecting long-term survivors (LTS) have been reported.
These include rev gene mutations (14), mutations
in vif, vpr, vpu, and nef
genes (22, 23) and deletions in the nef-long
terminal repeat (nef/LTR) region of HIV-1 strains
(6, 16, 27; R. Geffin, D. Wolf, R. Muller, M. Hill,
E. Stellwag, G. Scott, and A. Baur, Keystone Symp. HIV
Pathogenesis and Treatment 1998, abstr. 3027, 1998), and deletions in
the nef/LTR region have also been reported for HIV-2
(32).
The largest study of LTS infected with a defective HIV-1 strain has
been the Sydney Blood Bank Cohort (SBBC) identified in Australia
(5, 19, 20, 21, 24). This cohort consists of eight
individuals who became infected with a common nef-defective strain of virus after being transfused with blood products from a
common donor. After more than 16 years of infection, three of the
living cohort members have stable CD4 cell counts and undetectable viral loads (<20 RNA copies/ml of blood), and three, including the
donor, have declining CD4 cell counts and viral loads of 1,000 to
10,000 copies/ml (21). Most recently, the donor was
diagnosed with AIDS and has commenced highly active antiretroviral
therapy (HAART) (21), and one recipient has also been
treated because of declining CD4-positive lymphocyte counts.
There have been two other reports on the sequence structure of
nef-defective HIV-1 strains. One study identified a
hemophiliac whose virus had deletions in the nef/LTR region
(16) that increased in size over time. The other patient
acquired HIV-1 infection through sexual intercourse (27) and
was infected with a virus containing deletions in nef alone
and LTR regions, although wild-type LTR sequences were also present in
this patient. These individuals both had undetectable viral loads. The
hemophiliac had no reported AIDS-related infections and was reported to
have a decline in CD4-positive cell numbers despite low viral loads
that was reversed by HAART in 1998 (12). These observations,
taken with those from the SBBC, suggest that infection with
nef-defective viruses can lead to immune deficiency even
when viral loads in the plasma are low to undetectable (less than 200 copies of RNA/ml). However, it is also apparent that individuals
infected with these strains have a significantly longer survival time
than patients infected with wild-type strains of HIV-1.
In an analysis of viral and host factors associated with long-term
nonprogression, 70 persons enrolled in the Australian LTNP study
(2) were screened for nef/LTR deletions,
mutations in the vif, vpr, and vpu
accessory genes, and virus tropism based on env V3
loop sequence. Three LTS infected with HIV-1 strains with
different nef/LTR deletions were detected. These three had envelope sequences characteristic of macrophagetropic viruses, and one
had point mutations in the vif and vpr
genes leading to truncated open reading frames (ORFs).
Study group and sample preparation.
The LTS studied in this
group were enrolled in the Australian Long-Term Nonprogressor Study
(2). All had documented evidence of asymptomatic HIV-1
infection for at least 8 years, with a history of CD4-positive
lymphocyte counts of Amplification of nef/LTR.
Proviral sequences
were amplified using Taq DNA polymerase (Roche Diagnostics)
and a sensitive triple-nested PCR protocol. The first round used the
primers Nef5'5' (equivalent to nucleotides [nt] 8552 to 8573 of
HIV-1NL4-3) and CL6 at a final concentration of 400 nM, the
second round used primers Hpa5' (equivalent to nt 8637 to 8659) and
LTR3' at 200 nM, and the third round combination was Nef5' and LTR3',
also used at 200 nM. The sequences and coordinates of primers CL6,
Nef5', and LTR3' have been reported previously (5). The
cycling conditions for the primer sets were 94°C for 120 s,
followed by 35 cycles of 94°C for 15 s, 55°C for 15 s, and 72°C for 80 s, and a final elongation step of 72°C for 7 min. The cycling conditions for the second- and third-round primers were the same as for the first except the elongation time for the 35 cycles was 60 s at 72°C.
Deletion primers.
Primers were made to
HIV-1NL4-3 sequences in the deleted region of the
nef/LTR of LTS 3 (nt 9117 to 9138), LTS 9 (nt 9290 to 9311),
and LTS 11 (nt 9242 to 9261) and were used in place of LTR3' in the
triple-nested PCR amplification.
Amplification of the envelope V3 region.
The V3 loop was
amplified using a nested PCR protocol and primers DR16 (nt 6515 to 6539 of HIV-1NL4-3) and M13R12 (5'-M13R-+, nt 8007 to 8028),
DR16 and DR19 (nt 7691 to 7714), and a final round with M13F11
(5'-M13F-+, nt 6532 to 6556) with DR19. M13R refers to the addition of
the M13 reverse universal primer sequence (5'-TGCGGATAACAATTTCACACAGG-3') to the 5' end of the
HIV-1-specific primer sequence. Similarly, M13F refers to the addition
of the M13 forward universal primer sequence
(5'-TGCCACGACGTTGTAAAACGAC-3') to the 5' end of the primer.
The primer concentrations and cycling conditions were as described for
the nef/LTR region.
Accessory gene amplification.
The region of the HIV-1 genome
containing the accessory genes vif, vpr, and
vpu (equivalent to nt 4945 to 6372 of
HIV-1NL4-3) was amplified using a triple-nested protocol
consisting of a first round with primers V1F (nt 4651 to 4672) and V1R
(nt 6517 to 6542), a second with primers V2F (nt 4820 to 4843) and V2R
(nt 6456 to 6479), and a final round with primers V3F (nt 4945 to 4969)
and V3R (nt 6347 to 6372). All coordinates are given relative to
HIV-1NL4-3. Primer concentrations and conditions for
amplification were essentially those for the nef/LTR region
except that Expand High Fidelity polymerase mix (Roche Diagnostics) was
used in place of Taq polymerase together with an extension
time of 2 min at 72°C.
Sequencing.
Either amplimers were blunt ended, cloned, and
sequenced or uncloned products were sequenced following amplification
with primers containing M13 forward or M13 reverse tails as described previously (24). Sequences were aligned and analyzed
using GeneWorks software (Oxford Molecular Group).
Nucleotide sequence accession numbers.
The
nef/LTR, vif, vpr, vpu, and
env sequences described in this study have been deposited in
GenBank under accession numbers AY005982 to AY006090.
Identification of three LTS with deleted nef/LTR
regions.
Seventy HIV-1-infected LTS were recruited as part of a
study on Australian long-term nonprogressors. Of the 70, 59 participants had viral loads of greater than 200 RNA copies/ml of
plasma, and 11 had viral loads of less than 200 RNA copies/ml of
plasma. From a single attempt to amplify the nef/LTR region
using triple-nested PCR, 54 of the 59 participants with viral loads of
greater than 200 copies/ml of plasma yielded a positive
nef/LTR amplimer, all of which were wild type in size.
Thirty of these were chosen at random to represent viruses from
participants with a viral load spread from >200 to over 10,000 RNA
copies/ml of plasma. These PCR amplimers were cloned and sequenced, all
yielding wild-type Nef ORF (L. J. Ashton, D. I. Rhodes, A. Solomon, L. Deacon, C. Satchell, A. Carr, D. Cooper, R. Biti, G. Stewart, and J. M. Kalder, submitted for publication). The
nef/LTR region was successfully amplified, often requiring
more than one attempt, from all remaining 11 LTS with viral loads of
less than 200 RNA copies/ml. Of these, three, LTS 3, 9, and 11, yielded
only nef/LTR PCR amplimers smaller than wild-type HIV-1. LTS
3 had a viral load of less than 20 copies RNA/ml of plasma using the
ultrasensitive Amplicor HIV-1 assay, and amplification of the
nef/LTR and accessory gene regions from this individual was
by far the most difficult. To amplify required a product from LTS 3 required at the very least twice as many PCR attempts as were required
from the other LTS, even compared to three other LTS in the group with
viral loads of <60 copies RNA/ml of plasma. The other two LTS, LTS 9 and LTS 11, with deletions in the nef/LTR region had viral
loads of <200 copies RNA/ml of plasma using the standard Amplicor
assay. Epidemiological studies indicated that these three LTS acquired
HIV-1 through sexual contact with different people (2).
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Characterization of Three nef-Defective Human
Immunodeficiency Virus Type 1 Strains Associated with Long-Term
Nonprogression
for the Australian Long-Term Nonprogressor Study
Group
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
500 cells/µl and no antiretroviral therapy. On
recruitment to the study, blood samples were collected and tested for
serological reactivity to HIV-1 proteins. All participants tested
positive (2). Peripheral blood mononuclear cells (PBMCs) were isolated from these venous blood samples using density gradient centrifugation on Ficoll-Hypaque. Washed PBMCs were resuspended and
lysed at a concentration of 5 × 106 to 10 × 106 cells/ml in PCR lysis buffer (24). Viral
loads were measured using the Amplicor HIV-1 monitor assay (Roche
Molecular Systems, Branchburgh, N.J.).
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Characteristics of nef-defective LTS with
undetectable levels of HIV-1 RNA in plasma
|
32 allele (31)
(Table 1).
Sequence analysis of nef/LTR regions from LTS 3, 9, and
11.
Sequencing of both cloned and uncloned nef/LTR
products (24) amplified from LTS 3 (December 1995 and
September 1998 samples) revealed an in-frame deletion of 6 bp from the
5' end of the nef gene, beginning at nt 8815 relative to
HIV-1NL4-3. This corresponds to the loss of two amino
acids, equivalent to amino acids 10 and 11 of HIV-1NL4-3
Nef, from an area of known sequence polymorphism (29). A
further 29 bp of sequence was also deleted from the U3 region beginning
at nt 9113 (Fig. 1). The remaining sequence is like that of wild-type
strains, retaining regions essential for viral replication and, unlike
the SBBC strains, contains no alterations in the enhancer and basal
promoter regions (NF-
B and Sp1 binding regions, nt 9425 to 9484 of
HIV-1NL4-3). Amplification of the nef/LTR region
from the September 1998 sample using an Expand High Fidelity polymerase
mix yielded an identical nef/LTR product. The 29-bp deletion
resulted in a change in reading frame, yielding a truncated Nef ORF of
110 amino acids, compared with 206 amino acids for Nef of
HIV-1NL4-3, and 4 additional non-Nef amino acids before an
in-phase termination codon. Of the four conserved amino acid blocks of
Nef (defined by Shugars et al. [29]), the encoded
110-amino-acid protein of LTS 3 contains conserved block A and half of
block B but lacks blocks C and D (Fig. 2)
and therefore is unlikely to be fully functional. The expression of
this Nef protein has not been determined.
|
/RBF-2 binding region immediately 5' of NF-
B site II (Fig. 1). This duplication is known
as the most frequent naturally occurring HIV-1 length polymorphism (9).
Translation of the largest sequence, 796 bp, gave a Nef ORF encoding to
amino acid 74, although it lacks 12 amino acids, from positions 30 to
41 inclusive relative to HIV-1NL4-3. After amino acid 74, the reading frame changes, encoding a further 20 non-Nef amino acids
before a premature stop codon. The putative Nef protein contains only
half of conserved block A and does not contain the other three
conserved blocks (Fig. 2). Translation of the smaller sequences, 610 and 435 bp, gives a Nef ORF of only 4 amino acids before an in-phase
termination codon (Fig. 2).
The sequences of the 591- and 776-bp nef/LTR products from
LTS 11 both lacked 79 nt from the nef-alone region between
nt 8961 and 9039 relative to the HIV-1NL4-3 sequence. This
deletion removes sequence coding for the Pxx repeat of Nef
(29) and results in a Nef ORF of only 56 amino acids due to
the introduction of a termination codon after the first deletion. The
Nef ORF does not encode any of the conserved Nef blocks (Fig. 2). The
deletions in the nef/LTR overlap region differ in size
between these two populations (Fig. 1). The majority of clones lacked
the negative regulatory element region (nt 9188 to 9343), although 3 of
the 10 clones sequenced lacked only 18 bp (nt 9240 to 9257) from this region.
Absence of full-length nef/LTR sequences in LTS 3, 9, and 11. To determine whether wild-type nef/LTR sequences were also present in LTS 3, 9, and 11, primers were made to HIV-1NL4-3 sequences in the deleted regions and used in conjunction with Nef5' in a triple-nested PCR amplification. In addition to reamplification from PBMCs, second-round PCRs that yielded the deleted nef/LTR fragments were also amplified with the appropriate deletion primers. In no instance did products result from the use of the deletion primers on samples from the three LTS. Amplification of control HIV-1NL4-3 PBMC lysates gave expected amplimers of 460, 633, and 583 bp for deletion primers LTS 3, 9, and 11, respectively, at a sensitivity of 1 copy per 100,000 cells. Taken together with the absence of any full-length nef/LTR products from other PCR amplifications, these results indicate that full-length nef/LTR sequences are not present in PBMCs from these LTS.
Envelope V3 sequences indicate that viruses are
macrophagetropic.
Several attempts to culture virus from PBMCs
from the three LTS were unsuccessful even when CD8 cell depletion
coculture techniques were used (2). To determine the tropism
of these viruses, the V3 loop region of the envelope gene was amplified
and sequenced. The resulting sequences from LTS 3, 9, and 11 were
translated, giving peptides with overall charges of positive 4, 2, and
3, respectively, at pH 7. No sequences had positively charged amino acids at both the 306 and 320 amino acid positions, and as the V3 loop
is acidic (Fig. 3), the viruses are
likely to be macrophagetropic (7, 10). The amino acid
sequence GPER present at the tip of the V3 loop in LTS 3 is unusual and
has been reported only once (18).
|
Accessory gene sequences from LTS 3 encode only truncated Vif.
To ascertain whether there are defects in other HIV-1 genes which might
contribute to the viral loads of <200 RNA copies/ml of plasma in the
11 individuals, we amplified and sequenced their proviral
vif, vpr, and vpu genes and the first
coding exons of the tat and rev gene regions. Of
the 11 screened, only clones from LTS 3 possessed only truncated Vif
ORFs. As encountered with the amplification of the nef/LTR
region from LTS 3, amplification of the accessory gene region was also
the most difficult of all LTS studied. Of 11 attempts to amplify the
accessory gene region from the LTS 3 December 1995 sample, only 1 was
successful, and of eight independent PCR attempts on the LTS 3 September 1998 sample, two were successful. These were all cloned and
sequenced (Fig. 4A). Typically for other
LTS with viral loads of <200 RNA copies/ml of plasma, only one or two
PCR attempts were necessary to yield the desired product. Analysis of
amplimers from LTS 9 and 11 also had several novel single amino acid
differences from those reported previously (1, 18) and are
described in more detail below.
|
LTS 9 and 11 contain full-length accessory genes. The accessory gene region amplified from LTS 9 yielded a full-length Vif ORF of 192 amino acids in two of five clones. A third had an ORF of 173 amino acids. The two clones encoding full-length Vif ORF also contained full-length ORFs for Vpr (96 amino acids) and Vpu (81 amino acids) (Fig. 4B). The other three clones gave a Vpr ORF of 17 amino acids and a Vpu ORF of 22 amino acids. Of the clones with full-length ORFs, several unreported amino acid variations were observed, Vif-encoded amino acid variation H183R and Vpr-encoded variation E48A (Fig. 4B). The effect of these variations on the function of the accessory proteins is unknown. All clones gave intact first coding exons for rev and tat.
Sequences from the accessory gene region from LTS 11 yielded full-length ORFs for the vif, vpr, and vpu genes and the first exons of rev and tat. Several amino acid variations from the HIV-1NL4-3 sequence were observed, and those previously unreported were, in Vif K63I, H73N and conservative amino acid changes in Vpr(V31I) and in Vpu(I26V) (Fig. 4B). It is not known whether these variations have an effect on the function of the proteins.| |
DISCUSSION |
|---|
|
|
|---|
Of the almost 5% of HIV-1-positive individuals who are LTS, our study shows that approximately 4% (3 of 70) of the individuals in the Australian LTNP cohort are infected with viruses containing nef-defective genomes. These represent 3 of 11 individuals in the study who had viral loads of <200 copies of RNA/ml.
The three new nef-defective HIV-1 strains identified in this
study differ in sequence structure from the transfusion-transmitted SBBC strains of virus previously identified in Australia (5) in two significant respects. First, the LTS identified in the present
study contain nucleotide sequence in a region (nt 9281 to 9438) deleted
in all SBBC strains, and second, they lack the duplications and
rearrangements in the NF-
B and Sp1 transcription factor binding
domains characteristic of SBBC strains. Second, the majority of clones
(7 of 10) from LTS 11 and three of nine clones from LTS 9 lack a
purine-rich sequence block, reported to be an NF-AT binding region
(28), that is conserved in all SBBC strains (Fig. 1). The
possible index partner of LTS 9 appears to be infected with a wild-type
strain of HIV-1 (D. Rhodes, unpublished data). The deletions observed
in the three LTS viruses described here also differ from each other and
from those of other nef-deleted HIV-1 strains reported
elsewhere (16, 27), indicating that in general, regions not
essential for replication are equally susceptible to deletion. Sequence
differences in the auxiliary genes, env V3 loop, and
nef/LTR regions as well as differences in the number and
location of nef/LTR deletions indicate that these strains of
HIV-1 are unrelated.
The strains identified in this study retain all the basic elements of the nef/LTR region required for replication, namely, the polypurine tract, the start of the U3 region, and the enhancer and basal promoter regions. The strain found in LTS 3 is unique among nef-defective strains, as no provirus with full-length nef/LTR or Vif ORF could be found in any of the samples analyzed. These results suggest the presence of a strain defective in both nef and vif. The difficulty in amplifying viral sequences, the undetectable viral loads (<20 copies of RNA/ml of plasma), and the inability to culture virus from this individual make it difficult to prove conclusively that these defects occur together in the same virus genome. However, these properties are consistent with the replication of primate lentiviruses that contain multiple accessory gene defects (8). During the amplification procedure, a proofreading polymerase was used to negate PCR error as a factor in the detection of truncated Vif ORFs. Intrasample sequence variation was also observed among clones from LTS 3, indicating that more than one truncated Vif template molecule was amplified. Unexpectedly, no clones containing stop codons at both amino acids 37 and 68 were found. However, these different-length ORFs were amplified from samples collected at different times; the 37-amino-acid ORF was present in the more recent sample, whereas only the 68-amino-acid ORF was detected in the earlier sample. Clones from this sample also had an additional stop codon at amino acid 174, and therefore the production of a full-length Vif protein would require more than one reversion. The presence of the mutation at 174 also abolishes the wild-type start codon for Vpr, and no Vpr clones that had a start codon were found in the more recent (September 1998) sample. Mutations in Vpr have previously been shown to be associated with long-term nonprogression (23, 33). Further attempts are being undertaken to determine whether full-length Vif ORFs are or ever were present in this LTS by testing for antibodies to different peptides from Vif using an enzyme-linked immunosorbent assay technique similar to that described for Nef (13).
It is also somewhat surprising that the small nef/LTR deletion seen in LTS 3 persisted, as it has been reported that small deletions, albeit an in-frame 12-bp deletion, in the nef gene of simian immunodeficiency virus (SIV) was readily repaired to wild-type Nef sequences with loss of attenuation of the virus (34). Together with the defects in the nef gene, the defects in vif of LTS 3 would be expected to contribute significantly to the low viral loads (less than 20 copies/ml) and the inability to isolate virus from this individual, as Vif-defective HIV-1 very poorly infects PBMCs (11). Further evidence to suggest the presence of a highly attenuated virus is the absence of cytotoxic T-lymphocyte effector cell responses in this individual (E. Keoshkenan, L. J. Ashton, D. G. Smith, J. B. Ziegler, G. J. Stewart, J. M. Kaldor, D. A. Cooper, and R. Ffrench, submitted for publication). In addition, with this reduced replication capacity the repair of the small nef/LTR deletion and the truncated Vif ORF would be less likely to occur.
The size of the defective nef/LTR amplified from LTS 9 appears to be decreasing over time, suggesting an evolution of the defective nef/LTR sequences. Studies by us and others (16; D. Rhodes, A. Solomon, D. McPhee, and N. Deacon, Abstr. XIth Int. Cong. Virol. 1999, abstr. VW23.06) have demonstrated the evolution of nef-defective HIV-1 strains by additional deletions in this region. Similar evolution of the nef/LTR region has also been observed in nef-defective SIV strains in macaques that progress to AIDS (3, 17). The results from our studies with the SBBC strain of HIV-1 (Rhodes et al., abstr. 1999) indicate that the smaller viruses have a replication advantage over the larger ones, highlighting the importance of monitoring viral loads and viral quasispecies in LTS containing nef-defective viruses. In addition to the defective nef genes in LTS 9, all clones were found to encode Vpr with an unusual E48A difference compared with HIV-1NL4-3. The effect of this nonconservative amino acid difference on Vpr structure and function remains to be investigated.
Sequences from LTS 11 showed a nef-defective virus strain
that maintains a Nef ORF of 56 amino acids, although presumably it is
not fully functional due to the absence of conserved Nef regions. This
strain also encodes a Vif protein with a previously unreported
difference from other sequences, the nonconservative K63I substitution.
Whether this has any effect on the structure and function of Vif is not
known, and therefore any contribution of this difference to the low
viral load remains to be determined. In addition to the contribution of
a nef-defective virus to long-term nonprogression, LTS 11 is
heterozygous for the CCR5
32 allele.
In all three LTS strains, defects are present in the LTR gene promoter region. Studies in this laboratory on the SBBC viruses (5) have demonstrated that deletions in the LTR region can alter a virus's ability to replicate (Rhodes et al., abstr.; unpublished data). It is likely, therefore, that these mutations, although somewhat different between strains, together with the nef deletions and the unusual variations observed in the accessory proteins, also contribute to the low viral loads and lack of progression in these LTS.
This study has also identified what appears to be a unique nef- and vif-defective strain of virus. If this virus is found to replicate productively, albeit at a much reduced level, it would provide valuable information regarding the pathogenicity in humans of HIV-1 defective in multiple genes. It is doubtful this strain would make a useful live attenuated virus vaccine candidate, as the level of protection is inversely correlated to the level of attenuation of the virus (15, 26). Studies in the SIV/macaque model using vif-defective SIV strains have failed to induce protective immune responses (15). Follow-up studies on these individuals will provide additional information regarding the contribution of nef to HIV-1 pathogenesis.
| |
ACKNOWLEDGMENTS |
|---|
We thank all of the study participants.
This work was supported by grants to the National Centre in HIV Virology and the National Centre in HIV Epidemiology and Clinical Research from the Australian National Council on AIDS and Related Diseases through the Commonwealth AIDS Research Grants Committee and the Macfarlane Burnet Centre for Medical Research Fund.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: AMRAD Operations, 576 Swan St., Richmond, Victoria 3121, Australia. Phone: 61-3-9208 4181. Fax: 61-3-9208 4100. E-mail: drhodes{at}amrad.com.au.
The Australian Long-Term Nonprogressor Study Group includes B. Anderson, A. Allworth, L. Ashton, D. Baker, G. Batty, R. Biti, M. Bloch, N. Bodsworth, C. Bourne, J. Byrne, A. Carr, K. Clare, D. Cooper,
E. Cummins, P. Cunningham, D. Couldwell, L. Dayan, N. Deacon, A. Dearden, N. Doong, F. Drummond, J. Ewan, R. Finlayson, R. Ffrench, V. Furner, B. Genn, R. Hain, J. Kaldor, J. Kidd, M. Law, A. Lloyd, R. McFarlane, D. McPhee, H. Michelmore, K. McGhie, M. McMurchie, K. Mutimer, C. Pell, J. Peterson, R. Price, D. Quan, J. Quin, H. Ree, D. Rhodes, M. Robertson, C. Satchell, D. Smith, A. Solomon, D. Spencer, G. Stewart, J. Sullivan, and J. Ziegler.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Alexander, L.,
E. Weiskopf,
T. C. Greenough,
N. C. Gaddis,
M. R. Auerbach,
M. H. Malim,
S. J. O'Brien,
B. D. Walker,
J. L. Sullivan, and R. C. Desrosiers.
2000.
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection.
J. Virol.
74:4361-4376 |
| 2. | Ashton, L. J., A. Carr, P. H. Cunningham, M. Roggensack, K. McLean, M. Law, M. Robertson, D. A. Cooper, and J. M. Kaldor. 1998. Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group. AIDS Res. Hum. Retroviruses 14:117-121[Medline]. |
| 3. | Baba, T. W., V. Liska, A. H. Khimani, N. B. Ray, P. J. Dailey, D. Penninck, R. Bronson, M. F. Greene, H. M. McClure, L. N. Martin, and R. M. Ruprecht. 1999. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5:194-203[CrossRef][Medline]. |
| 4. | Buchbinder, S. P., M. H. Katz, N. A. Hessol, P. M. O'Malley, and S. D. Homberg. 1994. Long-term HIV-1 infection without immunologic progression. AIDS 8:1123-1128[Medline]. |
| 5. |
Deacon, N. J.,
A. Tsykin,
A. Solomon,
K. Smith,
M. Ludford-Menting,
D. J. Hooker,
D. A. McPhee,
A. L. Greenway,
A. Ellet,
C. Chatfield,
V. A. Lawson,
S. Crowe,
A. Maerz,
S. Sonza,
J. Learmont,
J. S. Sullivan,
A. Cunningham,
D. Dwyer,
D. Dowton, and J. Mills.
1995.
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients.
Science
270:988-991 |
| 6. |
Dean, M.,
M. Carrington,
C. Winkler,
G. A. Huttley,
M. W. Smith,
R. Allikmets,
J. J. Goedert,
S. P. Buchbinder,
E. Vittinghoff,
E. Gomperts,
S. Donfield,
D. Vlahov,
R. Kaslow,
A. Saah,
C. Rinaldo,
R. Detels, and S. J. O'Brien.
1996.
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene.
Science
273:1856-1862 |
| 7. |
De Jong, J. J.,
A. De Ronde,
W. Keulen,
M. Tersmette, and J. Goudsmit.
1992.
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.
J. Virol.
66:6777-6780 |
| 8. |
Desrosiers, R. C.,
J. D. Lifson,
J. S. Gibbs,
S. C. Czajak,
A. Y. Howe,
L. O. Arthur, and R. P. Johnson.
1998.
Identification of highly attenuated mutants of simian immunodeficiency virus.
J. Virol.
72:1431-1437 |
| 9. | Estable, M. C., B. Bell, A. Merzouki, J. S. G. Montaner, M. V. O'Shaugnessy, and I. J. Sadowski. 1996. Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity. J. Virol. 70:4053-4062[Abstract]. |
| 10. |
Fouchier, R. A. M.,
M. Groenink,
N. A. Kootstra,
M. Tersmette,
H. G. Huisman,
F. Miedema, and H. Schuitemaker.
1992.
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.
J. Virol.
66:3183-3187 |
| 11. |
Gabuzda, D. H.,
K. Lawrence,
E. Langhoff,
E. Terwilliger,
T. Dorfman,
W. Haseltine, and J. Sodroski.
1992.
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.
J. Virol.
66:6489-6495 |
| 12. |
Greenough, T. C.,
J. L. Sullivan, and R. C. Desrosiers.
1999.
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1.
N. Engl. J. Med.
340:236-237 |
| 13. | Greenway, A. L., J. Mills, D. Rhodes, N. J. Deacon, and D. A. McPhee. 1998. Serological detection of attenuated HIV-1 variants with nef gene deletions. AIDS 12:555-561[Medline]. |
| 14. | Iversen, A. K., E. G. Shpaer, A. G. Rodrgio, M. S. Hirsch, B. D. Walker, H. W. Sheppard, T. C. Merigan, and J. I. Mullins. 1995. Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J. Virol. 69:5743-5753[Abstract]. |
| 15. | Johnson, R. P. 1999. Live attenuated AIDS vaccines: hazards and hopes. Nat. Med. 5:154-155[CrossRef][Medline]. |
| 16. |
Kirchhoff, F.,
T. C. Greenough,
D. B. Brettler,
J. L. Sullivan, and R. C. Desrosiers.
1995.
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.
N. Engl. J. Med.
332:228-232 |
| 17. |
Kirchhoff, F.,
H. W. Kestler III, and R. C. Desrosiers.
1994.
Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene.
J. Virol.
68:2031-2037 |
| 18. | Korber, B., B. Hahn, B. Foley, J. W. Mellors, T. Leitner, G. Myers, F. McCutchan, and C. Kuiken. 1997. Human retroviruses and AIDS database 1997. Los Alamos National Laboratory, Los Alamos, N.Mex. |
| 19. | Learmont, J., L. Cook, H. Dunckley, and J. S. Sullivan. 1995. Update on long-term symptomless HIV type 1 infection in recipients of blood products from a single donor. AIDS Res. Hum. Retroviruses 11:1[Medline]. |
| 20. | Learmont, J., B. Tindall, L. Evans, A. Cunningham, P. Cunningham, J. Wells, R. Penny, J. Kaldor, and D. Cooper. 1992. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 340:863-867[CrossRef][Medline]. |
| 21. |
Learmont, J.,
A. F. Geczy,
J. M. Mills,
L. J. Ashton,
C. H. Raynes-Greenow,
R. J. Garsia,
W. B. Dyer,
L. McIntyre,
R. B. Oelrichs,
D. I. Rhodes,
N. J. Deacon, and J. S. Sullivan.
1999.
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.
N. Engl. J. Med.
340:1715-1722 |
| 22. | Mariani, R., F. Kirchhoff, T. C. Greenough, J. L. Sullivan, R. C. Desrosiers, and J. Skowronski. 1996. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J. Virol. 70:7752-7764[Abstract]. |
| 23. | Michael, N. L., G. Chang, L. A. D'Arcy, P. K. Ehrenberg, R. Mariani, M. P. Busch, D. L. Birx, and D. H. Schwartz. 1995. Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J. Virol. 69:4228-4236[Abstract]. |
| 24. | Rhodes, D., A. Solomon, W. Bolton, J. Wood, J. Sullivan, J. Learmont, and N. Deacon. 1999. Identification of a new recipient in the Sydney blood bank cohort: a long-term HIV type 1-infected seroindeterminate individual. AIDS Res. Hum. Retroviruses 15:1433-1439[CrossRef][Medline]. |
| 25. | Roger, M. 1998. Influence of host genes on HIV-1 disease progression. FASEB J. 9:625-632. |
| 26. | Ruprecht, R. M., T. W. Baba, R. Rasmussen, Y. Hu, and P. L. Sharma. 1996. Murine and simian retrovirus models: the threshold hypothesis. AIDS 10(Suppl. A):S33-S40. |
| 27. |
Salvi, R.,
A. R. Garbuglia,
A. Di Caro,
S. Pulciani,
F. Montella, and A. Benedetto.
1998.
Grossly defective nef gene sequences in a human immunodeficiency virus type-1 seropositive long-term nonprogressor.
J. Virol.
72:3646-3657 |
| 28. |
Shaw, J. P.,
P. J. Utz,
D. B. Durand,
J. J. Toole,
E. A. Emmel, and G. R. Crabtree.
1988.
Identification of a putative regulator of early T cell activation genes.
Science
241:202-205 |
| 29. |
Shugars, D. C.,
M. S. Smith,
D. H. Glueck,
P. V. Nantermet,
F. Seiller-Moiseiwitsch, and R. Swanstrom.
1993.
Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo.
J. Virol.
67:4639-4650 |
| 30. |
Smith, M. W.,
M. Dean,
M. Carrington,
C. Winkler,
G. A. Huttley,
D. A. Lomb,
J. J. Goedert,
T. R. O'Brien,
L. P. Jacobson,
R. Kaslow,
S. Buchbinder,
E. Vittinghoff,
D. Vlahov,
K. Hoots,
M. W. Hilgartner, and S. J. O'Brien.
1997.
Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression.
Science
277:959-965 |
| 31. | Stewart, G. J., L. J. Ashton, R. A. Biti, R. A. Ffrench, B. H. Bennetts, N. R. Newcombe, E. M. Benson, A. Carr, D. A. Cooper, and J. M. Kaldor. 1997. Increased frequency of CCR-5 and delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. AIDS 11:1833-1838[Medline]. |
| 32. | Switzer, W. M., S. Wiktor, V. Soriano, A. Silva-Graca, K. Mansinho, I.-M. Coulibaly, E. Ekpini, A. E. Greenberg, T. M. Folks, and W. Heneine. 1998. Evidence of Nef truncation in human immunodeficiency virus type 2 infection. J. Infect. Dis. 177:65-71[Medline]. |
| 33. | Wang, B., Y. Ge, S. H. Palasanthirin, J. Xiang, J. Ziegler, D. E. Dwyer, C. Randle, D. Dowton, A. Cunningham, and N. Saksena. 1996. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology 223:224-232[CrossRef][Medline]. |
| 34. | Whatmore, A. M., N. Cook, G. A. Hall, S. Sharpe, E. W. Rud, and M. P. Cranage. 1995. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J. Virol. 69:5117-5123[Abstract]. |
| 35. | Zhang, L., Y. Huang, H. Yuan, S. Tuttleton, and D. D. Ho. 1997. Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection. Virology 228:340-349[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|